---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-093768"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:43:52.688975+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar to sell Huntsville PEGylation plant to Ampersand for $90M

## Summary
- Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).
- Expected close by Dec 2, 2024; all Huntsville employees offered jobs at new co.
- Nektar retains existing royalty/milestone rights; enters supply agreements for PEG reagents.
- Sale not subject to financing; extends Nektar cash runway into Q4 2026.

## SEC filing metadata
- accession: 0001213900-24-093768
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390024093768/0001213900-24-093768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390024093768/ea0219747-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-093768
- JSON: https://secwatch.observer/filing/0001213900-24-093768.json
- Plain text: https://secwatch.observer/filing/0001213900-24-093768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.